The Medical Advisor

Ray-Ban Meta Audio for blind and low-vision users raises an important question: Is removing the camera an improvement in accessibility, or a step backward? The answer depends on what someone needs from their glasses. Camera-free smart glasses can offer hands-free calls, music, an AI assistant and other audio-based conveniences without recording images through a built-in camera. However, a camera is also what enables compatible smart glasses to describe surroundings, help identify objects and read printed information aloud. Introduced by Meta in September 2026, Ray-Ban Meta Audio is the company's first audio-only AI glasses line. It starts at US$349 and offers up to 12 hours of battery life, with additional charging from its case. Unlike camera-equipped Ray-Ban Meta models, it cannot capture photos or videos. [1] For someone who primarily wants hands-free audio and greater privacy, this design makes sense. For someone who depends on AI to interpret visual information, the...

By Dr. Frank Yap, MD  · One Day Media Network · Last Updated October 2026 Quick Answer "GLP-1 2.0" is the second wave of obesity medicines built on semaglutide and tirzepatide. It improves on the first wave in five ways: more potency (retatrutide, a triple agonist, averaged 28.3% weight loss at 80 weeks in Lilly's TRIUMPH-1 trial), new mechanisms (amylin and glucagon), easier formats (daily pills already approved; monthly injections in Phase 3), better body composition , and lower prices . As of September 29, 2026, no next-generation injectable is approved yet : retatrutide's FDA filing is planned for Q1 2027 and CagriSema's FDA decision is expected in late 2026. Approved 2.0-era products today are the oral drugs (Wegovy pill, Foundayo) and high-dose Wegovy HD. Disclosure: This article is educational and is not medical advice. ...

Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Published: March 2026 | Last updated: October 6, 2026 Quick Answer As of October 2026, tirzepatide (Zepbound) is the strongest FDA-approved option at about 20–21% average weight loss, ahead of semaglutide (Wegovy) at about 15% (20.7% at the new 7.2 mg dose). Retatrutide, a triple agonist, reached 28.3% at 80 weeks in Phase 3 but is not FDA-approved ; Lilly plans to file in Q1 2027. What changed in this update (Oct 2026): replaced pre-Phase-3 estimates with TRIUMPH-1/2/3 results; corrected retatrutide launch timing (not before late 2027); added Wegovy HD, the Wegovy pill, Foundayo and CagriSema context; removed claims sourced only from research-peptide vendors, forum posts and unverified preprints; added CEBM evidence tiers, FAQ and an AI-prompt guide. Contents At-a-glance comparison How the three work What the trials show (and don't) Retatrutide: status in October 2026 Muscle and lean...